Login / Signup

Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology.

Malte W VetterleinStephanie A M WankowiczThomas SeisenRichard LanderBjörn LöppenbergFelix K-H ChunMani MenonMaxine SunJustine A BarlettaToni K ChoueiriJoaquim BellmuntQuoc-Dien TrinhMark A Preston
Published in: Cancer (2017)
Patients with neuroendocrine tumors benefit from neoadjuvant chemotherapy, as evidenced by better overall survival and lower rates of non-organ-confined disease at the time of RC. For tumors with micropapillary differentiation, sarcomatoid differentiation, or adenocarcinoma, neoadjuvant chemotherapy decreased the frequency of non-organ-confined disease at the time of RC. However, this favorable effect did not translate into a statistically significant overall survival benefit for these patients, potentially due to the aggressive tumor biology. Cancer 2017;123:4346-55. © 2017 American Cancer Society.
Keyphrases